Hemostatic injection needle coated with crosslinked chitosan having catechol group and oxidized catechol group

a technology of chitosan and injection needle, which is applied in the direction of coating, surgery, pharmaceutical delivery mechanism, etc., can solve the problems of significant low solubility in neutral solutions, the development of materials having excellent adhesion to tissue, and the inability to meet all the adhesive strength requirements, so as to prevent bleeding

Active Publication Date: 2018-03-29
INNOTHERAPY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007]It is an object of the present invention to provide an injection needle coating hydrogel for preventing bleeding during and after injection.

Problems solved by technology

However, such hemostatic and adhesive products do not satisfy all of adhesive strength, long-lasting properties after application, low toxicity, in vivo immune responses, etc.
Thus, in the development of hemostatic agents, the development of materials having biocompatibility while having excellent adhesion to tissue has become an important issue.
However, chitosan has disadvantages in that it has significantly low solubility in neutral solutions and is soluble only in acidic solutions.
Due to such disadvantages, the use of chitosan as a medical material is limited.
However, the formulation as described above is a form developed in view of convenience of surgical operations, and has a problem in that it does not satisfy all of adhesive strength, long-lasting properties after application, low toxicity, in vivo immune responses, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hemostatic injection needle coated with crosslinked chitosan having catechol group and oxidized catechol group
  • Hemostatic injection needle coated with crosslinked chitosan having catechol group and oxidized catechol group
  • Hemostatic injection needle coated with crosslinked chitosan having catechol group and oxidized catechol group

Examples

Experimental program
Comparison scheme
Effect test

preparation example 1

Preparation of Chitosan Introduced with Catechol

[0072]

[0073]3 g of about 30% acetylated chitosan (chitosan 70 / 100, model: 24204, manufactured by Heppe Medical Chitosan) was dissolved in 292 mL of HCl solution (pH=2) for 6 hours. The chitosan solution was adjusted to a pH of 5.5 by slowly adding 8 mL of 0.5 N NaOH solution thereto. The prepared 1% chitosan solution was stabilized for 12 hours.

[0074]To the prepared chitosan solution, 2.37 g of 3-(3,4-dihydroxyphenyl)propanoic acid was added. Then, as a reactant for forming an amide bond (—CONH—) between the amine (—NH2) group of the chitosan and the carboxyl group (—COOH) of 3-(3,4-dihydroxyphenyl)propanoic acid, 2.02 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) was dissolved in 50 mL of ethanol and added to the chitosan solution. Next, the solution was adjusted to a pH of 4.5, and then allowed to react for 1 hour. In this process, a catechol-functionalized chitosan was prepared.

[0075]To remove unreacted 3-(3,4-dihydroxyph...

example 1

Manufacture 1 of Hemostatic Injection needle (26 G)

[0076]1.5 mL of the catechol-functionalized chitosan prepared in Preparation Example 1 was dissolved in 100 μL of triple-distilled water, and then stored at 4° C. for 3 days to induce partial oxidation and cross-linking of the catechol group. As a result, a chitosan solution (hereinafter referred to as “chitosan-catechol solution” was prepared in which the catechol group

and the oxidized catechol group

were introduced and partially cross-linked.

[0077]The degree of oxidation of the catechol group in the chitosan-catechol solution was determined by measuring the absorbance at a wavelength of 500 nm by UV-Vis spectrometry. When a cross-link between the oxidized catechol group and the amine group of the chitosan is formed, the absorbance at a wavelength of 500 nm appears. Thus, based on the absorbance appearing the chitosan-catechol solution was treated with NaIO4 (that is an oxidizing agent that induces oxidation of the chitosan-catechol...

example 2

Manufacture 1 of Hemostatic Injection needle (23 G)

[0079]A hemostatic injection needle was manufactured in the same manner as described in Example 1, except that a 23 G-thick injection needle was used instead of the 26 G-thick injection needle and that the chitosan-catechol solution was used in an amount of 9 μL instead of 6.5 μL.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a hemostatic injection needle coated with a chitosan in which a catechol group and an oxidized catechol group are introduced and cross-linked. The hemostatic injection needle according to the present invention can suppress bleeding during and after injection, and thus can be effectively used for injection not only into coagulopathy patients, including diabetic patients, patients under anticancer treatment, and haemophilia patients, who have a low hemostatic ability, but also into patients showing blood rejection responses, and children.

Description

TECHNICAL FIELD[0001]The present invention relates to a hemostatic injection needle coated with a chitosan in which a catechol group and an oxidized catechol group are introduced and cross-linked.BACKGROUND ART[0002]The development of conventional hemostatic and adhesive products has been focused on their use in surgical operations. Typical medical hemostatic agents and adhesives include cyanoacrylate-based adhesives approved by the FDA, and fibrin glue based on in vivo blood clotting protein. However, such hemostatic and adhesive products do not satisfy all of adhesive strength, long-lasting properties after application, low toxicity, in vivo immune responses, etc. Thus, in the development of hemostatic agents, the development of materials having biocompatibility while having excellent adhesion to tissue has become an important issue.[0003]Meanwhile, chitosan is widely known as a biopolymer having an excellent hemostatic ability. However, chitosan has disadvantages in that it has s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61L31/10A61L31/14A61L31/16
CPCA61L31/10A61L31/145A61L31/16A61L2300/236A61L2420/02A61L2400/04A61L31/14C08L5/08
Inventor LEE, HAESHINSHIN, MIKYUNGLEE, MOON SUEOH, SUK SONG
Owner INNOTHERAPY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap